{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"22"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"25"}],"units":"Participants"}],"description":"The overall survival is the time from treatment initiation to death.","groups":[{"description":"Following dose escalation, an additional 25 patients will receive ABI-009 at the MTD and defined doses of nivolumab to assess overall safety and potential efficacy in a greater number of patients. Patients in the expansion phase of the study may continue treatment up to 18 three-week cycles or until significant disease progression or unacceptable toxicity occurs.","id":"OG000","title":"Expansion Phase 1b"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Per pre-specified analysis, only participants in the expansion phase of the study were evaluated.","reportingStatus":"POSTED","timeFrame":"30 weeks","title":"Overall Survival","type":"SECONDARY","unitOfMeasure":"Participants"}